Luxturna shortage — ES supply status & alternatives

Luxturna

—

🇦🇺 AUST R 318929 · Novartis Pharmaceuticals Australia Pty Ltd

In supply · Australia

In supply · 🇦🇺 Australia · short in🇪🇸 ES

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Marketing-authorisation holders
Active ingredient (INN)	Luxturna
Therapeutic category	Auto-created by Agencia Española de Medicamentos — Problemas de Suministro scraper
Controlled substance	No

Registrations on file	4

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders4 registrations · 4 MA holders

Product	Strength	Form	Market	MA holder	Status
LUXTURNA voretigene neparvovec	—	—	🇦🇺 AU	Novartis Pharmaceuticals Australia Pty Ltd	Active
LUXTURNA	—	kit	🇺🇸 US	Spark Therapeutics, Inc.	Active
Luxturna	—	—	🌐 EU	Novartis Europharm Limited	Active
LUXTURNA	—	solution	🇨🇦 CA	NOVARTIS PHARMACEUTICALS CANADA INC	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.